Skip to main content

Advertisement

SpringerLink
Log in

Beyond Palliative Mastectomy in Inflammatory Breast Cancer—A Reassessment of Margin Status

  • Original Article
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Inflammatory breast cancer is a locally advanced tumor with an aggressive local and systemic course. Treatment of this disease has been evolving over the last several decades. The aim of this study was to assess whether current therapies, both surgical and chemotherapeutic, are providing better local control (LC) and overall survival (OS). We also attempted to identify clinical and pathologic factors that may be associated with improved OS, disease-free survival (DFS), and LC.

Methods: A 25-year retrospective review performed at the City of Hope National Medical Center identified 90 patients with the diagnosis of inflammatory breast cancer.

Results: Of the 90 patients identified with inflammatory breast cancer, 33 received neoadjuvant therapy (NEO) consisting of chemotherapy followed by surgery with radiation (n = 26) and without radiation (n = 7). Fifty-seven patients received other therapies (nonNEO). Treatments received by the nonNEO group consisted of chemotherapy, radiation, mastectomy, adrenalectomy, and oophorectomy, alone or in combination. The median follow-up was 28.9 months for the NEO group and 17.6 months for the nonNEO group. Borderline significant differences in the OS distributions between the two groups were found (P =.10), with 3- and 5-year OS for the NEO group of 40.0% and 29.9% and for the nonNEO group of 24.7% and 16.5%, respectively. DFS and LC were comparable in the two groups. Lower stage was associated with an improved OS (P < .05). The 5-year OS for stage IIIB was 30.9%, compared to 7.8% for stage IV. In those patients with stage III disease who were treated with mastectomy and rendered free of disease, margin status was identified by univariate analysis to be a prognostic indicator for OS (P < .05). The 3-year OS, DFS, and LC for patients with negative margins were 47.4%, 37.5%, and 60.3%, respectively, compared to 0%, 16.7%, and 31.3% in patients with positive margins.

Conclusions: This study suggests that in patients with inflammatory breast cancer and nonmetastatic disease, an aggressive surgical approach may be justified with the goal of a negative surgical margin. Achievement of this local control is associated with a better overall outcome for this subset of patients. The ability to obtain negative margins may further identify a group of patients with a less aggressive tumor biology that may be more responsive to other modalities of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Osteen RT, Cady B, Chmiel JS, et al. 1991 National survey of carcinoma of the breast by the Commission on Cancer. J Am Coll Surg 1994;178:213–221.

    CAS  PubMed  Google Scholar 

  2. Bell C. A System of Operative Surgery. vol 2. Hartford: Hale and Hosmer, 1814:136.

    Google Scholar 

  3. Haagensen CD, Stout AP. Carcinoma of the breast. II. Criteria of operability. Ann Surg 1943;118:859–870.

    CAS  PubMed  Google Scholar 

  4. Rogers CS, Fitts WT. Inflammatory carcinoma of the breast: a critique of therapy. Surgery 1956;39:367–370.

    CAS  PubMed  Google Scholar 

  5. Fields JN, Kuske RR, Perez CA, et al. Prognostic factors in inflammatory breast Cancer: univariate and multivariate analysis. Cancer 1989;63:1225–1232.

    CAS  PubMed  Google Scholar 

  6. Fields JN, Perez CA, Kruske RR, Fineberg BB, Bartlett N. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys 1989;17:249–255.

    CAS  PubMed  Google Scholar 

  7. Chu AM, Wood WC, Doucette JA. Inflammatory breast Cancer treated by radical radiotherapy. Cancer 1980;45:2730–2737.

    CAS  PubMed  Google Scholar 

  8. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer 1994;74:466–476.

    CAS  PubMed  Google Scholar 

  9. Zucali R, Uslenghi C, Kenda R, et al. Natural history and survival of inoperable breast Cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 1976;37:1422–1431.

    CAS  PubMed  Google Scholar 

  10. Hortobagyi GN, Buzdar AU. Progress in inflammatory breast cancer: cause for cautious optimism. J Clin Oncol 1986;4:1727–1729.

    CAS  PubMed  Google Scholar 

  11. Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986;4:1765–1771.

    CAS  PubMed  Google Scholar 

  12. Haagensen CD. Inflammatory carcinoma. In: Diseases of the Breast, 3rd edn. Philadelphia: WB Saunders, 1986:808–814.

    Google Scholar 

  13. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast: a pathologic definition. Cancer 1974;33:1045–1047.

    CAS  PubMed  Google Scholar 

  14. Saltzstein SL. Clinically occult inflammatory Cancer of the breast. Cancer 1974;34:382–388.

    CAS  PubMed  Google Scholar 

  15. Beahrs OH, Henson DE, Hutter RVP, Kennedy B (eds). Handbook for the Staging of Cancer. Philadelphia: JB Lippincott, 1993: 163–165.

    Google Scholar 

  16. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187–202.

    Google Scholar 

  17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Association 1957;53:457–481.

    Google Scholar 

  18. SAS Institute Inc. SAS Technical Report P-217, SAS/STAT Software: The PHREG Procedure Version 6. Cary, NC: SAS Institute Inc., 1991.

    Google Scholar 

  19. Kokal WA, Hill LR, Porudominsky D, Beaty JD, Kemeny MM, Riihimaki DU, Terz JJ. Inflammatory breast carcinoma: a distinct entity. J Surg Oncol 1985;30:152–155.

    Article  CAS  PubMed  Google Scholar 

  20. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1994;10:1014–1024.

    Google Scholar 

  21. Contesso G, May-Levin F, Delarue JC, et al. Inflammatory tumors of the human breast: determination of estrogen and progesterone receptors. Recent Results Cancer Res 1984;91:157–168.

    CAS  PubMed  Google Scholar 

  22. De Larue JC, May-Levin F, Mouriesse H, et al. Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumors of the human breast. Br J Cancer 1981;44:911–916.

    Google Scholar 

  23. McCready DR, Hortobagyi GN, Shu W, et al. The prognostic significance of lymph node metastasis after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989;124:21–25.

    CAS  PubMed  Google Scholar 

  24. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg 1994;18:87–92.

    CAS  PubMed  Google Scholar 

  25. Antman K, Bearman S, Davidson N, et al. Dose intensive therapy in breast cancer: current status. In: Gale RP, Champlin RE, eds. New Strategies in Bone Marrow Transplantation. New York: Alan R. Liss, 1990:423–426.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Keesler Medical Center, Keesler AFB, Mississippi

    Lisa D. Curcio MD

  2. Departments of Medical Oncology, City of Hope National Medical Center, Los Angeles, California

    George Somlo MD

  3. Therapeutics and Biostatistics, City of Hope National Medical Center, Los Angeles, California

    K. Clarke MS & Tamara Odom-Maryon PhD

  4. General and Oncologic Surgery, City of Hope National Medical Center, Los Angeles, California

    Elizabeth Rupp MD, Wydell L. Williams MD, David Z. J. Chu MD, Joshua D. I. Ellenhorn MD & Lawrence D. Wagman MD

  5. Surgical Oncology, 81st MSGS/SGCS, Keesler Medical Center, 301 Fisher Street, Keesler AFB, MS, 39534

    Lisa D. Curcio MD

Authors
  1. Lisa D. Curcio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth Rupp MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wydell L. Williams MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Z. J. Chu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Clarke MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tamara Odom-Maryon PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joshua D. I. Ellenhorn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. George Somlo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lawrence D. Wagman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curcio, L.D., Rupp, E., Williams, W.L. et al. Beyond Palliative Mastectomy in Inflammatory Breast Cancer—A Reassessment of Margin Status. Ann Surg Oncol 6, 249–254 (1999). https://doi.org/10.1007/s10434-999-0249-3

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-999-0249-3

Key Words

Search

Navigation